Prevest Denpro Ltd Q3 FY2024 Concall Summary

Key Takeaways

• Domestic boom offsets export stall: Domestic revenue surged 35% in 9M, absorbing a flat export performance caused entirely by a foreign-exchange crisis in four key markets, not by demand loss.
• Margins dipped on deliberate investment: EBITDA margin contracted as the company added a marketing team, ramped exhibition spend, and funded US FDA consultancy, a spend management frames as future-revenue-generating rather than a leak.
• Oradox launch opens a new front: The new oral-care brand is now live across Amazon, Flipkart, Tata 1mg and offline dentist channels, with products management claims are first-in-India and face no direct competition.
• Capacity is a non-issue: The plant runs at 40% on a single shift, enough headroom for five years of growth with no additional capex.
• What to watch next quarter: Whether the four FX-crisis countries actually reopen and release the pent-up demand management is banking on, and whether Oradox and the disinfectant segment begin contributing materially to the top line.

Export: The FX Blockade

• The problem is not demand: Customers in Egypt, Peru, Argentina and Sudan have funds and want product, but their governments lack foreign exchange to remit payment, freezing orders from four of the company's top 20 export markets.
• Flat 9M export revenue: Management held export revenue level with last year by finding new avenues in other countries, but the four blocked markets, previously maximum contributors, delivered no growth.
• New geographies added: Australia, Venezuela, Senegal, Mauritius and Saudi Arabia came onstream this year, with Saudi Arabia performing extremely well.
• US share rising: The US grew from 0.8% to 2.44% of revenue, and management sees a lot of opportunity there for the next financial year.
• Pent-up demand thesis: Management expects a surge when countries reopen, citing past experience that once a country opens, it releases pent-up demand. Orders are already starting to come in as signs of easing appear.

Atul Modi: "The crisis is basically the non-availability of foreign exchange with the governments. There is no problem with the demand and there is no problem with our customers. They have plenty of funds. But the governments in these countries do not have the foreign exchange. They cannot remit the foreign exchange because they have foreign exchange deficit."

Domestic Engine

• 35% growth in 9M: Management calls the domestic performance phenomenal, attributing it to a diligent marketing team and high product quality.
• Tier 3/4 cities lead growth: Growth has been led by smaller cities, though tier 1/2 cities still contribute a higher share of revenue; the difference between the two is not very high.
• Market-share ambition: Prevest holds the highest market share among Indian manufacturers, but the top 5-7 companies dominating the Indian market are all multinationals (Dentsply, GC Fuji, Coltene). Management aims to lift domestic share from 3% to 10-20% as early as possible.
• Dealer network expanding: The company continuously adds new dealers in unserved domestic cities and in export countries without representation.

Oradox & New Ventures

• Three-pronged go-to-market: Oradox is being pushed through online consumer marketing, offline engagement with dentist channel partners via the existing 60-plus-dealer network, and dental exhibitions.
• First-in-India positioning: Management claims Oradox products are innovative, most are first in India, and many are currently unavailable in the country, so direct competition with bigger players does not exist because the products are highly specialized.
• E-commerce channel live: The company launched its own platform, Prevest Direct, with pan-India delivery, and secured partnerships with Tata 1mg, Amazon and Flipkart for the Oradox range.
• Disinfectant segment in pre-launch: Products are undergoing evaluation and clinical trials in various institutions; management anticipates a significant top-line contribution in the coming period.
• R&D pipeline: Bone grafting materials, oral wound dressings and other products are under development and will be taken up for commercial production once fully developed.

Vaibhav Munjal: "These products are very innovative and most of them are first in India. And many of these kind of products are currently not available in India, and hence the direct competition to the bigger players in this market doesn't exist because these are very specialized products."

Margins & Cost Structure

• Marginal EBITDA decline: Profit margin and EBITDA margin decreased, attributed to strategic investments in launching and promoting Oradox, participation in domestic and international dental exhibitions, and actively expanding the team across departments.
• Headcount-driven cost rise: Employee benefit costs increased as the company added a marketing team led by Mr. Vaibhav Munjal, growing headcount from 100 to 141, mostly in marketing.
• Other expenditure jump: Exhibition expenses rose from exploring new markets worldwide, consultancy fees went up 2x-3x due to US FDA work, and fees/subscriptions climbed from ₹6.52 lakhs to ₹25.20 lakhs.
• Investment, not leakage: Management believes these expenditures will generate more sales revenue in coming quarters and is confident that focused cost-effective practices and diligent resource management will improve margins.

Competitive Position & Capacity

• Competition is multinational, not Chinese: Management does not consider Chinese products as competition due to quality concerns; the real competitors are Dentsply, GC Fuji, Coltene and similar multinationals.
• 40% utilization, five-year headroom: The plant operates at 40% on a single shift, can reach 90% on a single shift and further with a second shift, providing enough capacity for the next five years without additional capex.
• Main-board migration planned: The company plans to migrate to the main board from the next financial year.

Guidance & Commitments

Key Metrics